Who is the new CFO and what is his background?

Robert McMahon, age 56, previously served as CFO of Agilent Technologies Inc., as CFO of Hologic, Inc. from 2014 to 2018, and spent 20 years with Johnson & Johnson in executive financial roles. He has been an Independent Director at OraSure Technologies, Inc. since 2023. He holds an MBA from the University of Central Florida and a bachelor's degree from the University of Florida.

What is McMahon's compensation package?

He receives an initial annual base salary of $800,000 and a target annual incentive of 80% of base salary, prorated for 2025. He also receives an LTI award with a grant date fair value of $3,000,000 on August 11, 2025, a one-time cash sign-on bonus of $3,115,000, and a Replacement Equity Grant with a grant date fair value of $4,200,000. He is expected to receive annual LTI awards beginning in 2026.

Why was a sign-on bonus and replacement equity granted?

The filing states that the cash sign-on bonus and the Replacement Equity Grant are intended to partially compensate McMahon for near-term cash and equity incentives and long-term equity compensation he forfeited upon resigning from his prior employer.

What happens to the outgoing CFO?

Bernard Birkett, who previously announced his retirement, will serve as Senior Advisor to the CEO through December 31, 2025 to ensure a smooth transition.

What are the repayment terms on the sign-on bonus?

The cash sign-on bonus is subject to a two-year repayment obligation if McMahon voluntarily terminates employment on or before the second anniversary of the Commencement Date, other than for Constructive Termination, Death, or Disability, or if the Company terminates him for Cause, as defined in the Offer Letter.

WST 8-K: Leadership Changes

01—Abstract

Summary

Summary of the 8-K filed July 21, 2025. Cited figures are marked; the original filing is the authoritative source.

West Pharmaceutical Services, Inc. (NYSE: WST) announced on July 21, 2025 the appointment of Robert McMahon as Senior Vice President & Chief Financial Officer, effective August 4, 2025 (the Commencement Date).

McMahon will oversee finance, audit, treasury, tax, investor relations and procurement. He previously served as CFO of Agilent Technologies Inc., CFO of Hologic, Inc. from 2014 to 2018, and spent 20 years with Johnson & Johnson in executive financial roles. He succeeds Bernard Birkett, who is retiring and will serve as Senior Advisor to the CEO through December 31, 2025.

Under his Offer Letter dated July 11, 2025, McMahon receives an initial annual base salary of $800,000^a and a target annual incentive bonus of 80% of base salary, prorated for 2025. On August 11, 2025, he will receive a long-term incentive award with a grant date fair value of $3,000,000 (50% PSUs, 25% stock options, 25% RSUs), plus a one-time cash sign-on bonus of $3,115,000 and a sign-on Replacement Equity Grant with a grant date fair value of $4,200,000. The sign-on payments are intended to partially offset incentives forfeited at his prior employer, and the cash bonus carries a two-year repayment obligation.

For investors, the filing documents a planned CFO transition with a built-in overlap period for Birkett, and the compensation package is substantial relative to the stated base salary, largely reflecting sign-on replacement awards. The filing does not describe any change to West's financial results or guidance.

02—Key points

Key Highlights

Robert McMahon appointed SVP & CFO effective August 4, 2025, succeeding Bernard Birkett, who is retiring
McMahon's responsibilities include finance, audit, treasury, tax, investor relations and procurement
Base salary of $800,000 with a target annual incentive of 80% of base salary, prorated for 2025
Annual LTI award with grant date fair value of $3,000,000 on August 11, 2025, split 50% PSUs, 25% stock options, 25% RSUs
One-time cash sign-on bonus of $3,115,000 and Replacement Equity Grant with grant date fair value of $4,200,000, partly to offset forfeited prior-employer awards
Cash sign-on bonus subject to a two-year repayment obligation under specified termination scenarios
Birkett serves as Senior Advisor to the CEO through December 31, 2025 to support the transition

03—Questions

Frequently Asked Questions

Who is the new CFO and what is his background?
Robert McMahon, age 56, previously served as CFO of Agilent Technologies Inc., as CFO of Hologic, Inc. from 2014 to 2018, and spent 20 years with Johnson & Johnson in executive financial roles. He has been an Independent Director at OraSure Technologies, Inc. since 2023. He holds an MBA from the University of Central Florida and a bachelor's degree from the University of Florida.
What is McMahon's compensation package?
He receives an initial annual base salary of $800,000 and a target annual incentive of 80% of base salary, prorated for 2025. He also receives an LTI award with a grant date fair value of $3,000,000 on August 11, 2025, a one-time cash sign-on bonus of $3,115,000, and a Replacement Equity Grant with a grant date fair value of $4,200,000. He is expected to receive annual LTI awards beginning in 2026.
Why was a sign-on bonus and replacement equity granted?
The filing states that the cash sign-on bonus and the Replacement Equity Grant are intended to partially compensate McMahon for near-term cash and equity incentives and long-term equity compensation he forfeited upon resigning from his prior employer.
What happens to the outgoing CFO?
Bernard Birkett, who previously announced his retirement, will serve as Senior Advisor to the CEO through December 31, 2025 to ensure a smooth transition.
What are the repayment terms on the sign-on bonus?
The cash sign-on bonus is subject to a two-year repayment obligation if McMahon voluntarily terminates employment on or before the second anniversary of the Commencement Date, other than for Constructive Termination, Death, or Disability, or if the Company terminates him for Cause, as defined in the Offer Letter.

04—Continue

← View all 8-K filings